Carina Mallard is Professor of Experimental Perinatal Brain Injury Research and Pro-Vice-Chancellor at the University of Gothenburg since July 2023, where she oversees research infrastructure and chairs the Research Board. She previously served as Deputy Vice-Chancellor (2021–2023) and Head of Core Facilities (2018–2021). Her academic career began with a Physiology degree from Lund University and a PhD in Pediatrics at the University of Auckland (1995), followed by a professorship appointment in 2006. Her research focuses on perinatal brain injury , particularly in premature infants , investigating neuroinflammatory mechanisms maternal dietary interventions neurovascular unit dynamics microglia activation long-term consequences of maternal obesity . Recent publications highlight her work on neonatal rodent models , transcriptomic profiling , and anti-inflammatory therapies . Key themes include RNA degradation , mitochondrial protection , and immune-neurovascular interactions . She has supervised 20 doctoral students since 2004 and collaborates internationally with institutions like King's College London. Contact details include two institutional emails and physical addresses across Gothenburg's biomedical campuses. Her leadership roles span research strategy, doctoral education, and EU-level scientific initiatives.
Manuel R. Amieva is a Professor at Stanford University School of Medicine , holding joint appointments in Pediatrics - Infectious Diseases and Microbiology & Immunology . He is also a member of the Maternal & Child Health Research Institute (MCHRI) . His clinical practice at Stanford Medicine Children's Health focuses on pediatric infectious diseases. Education: Medical Education: Stanford University School of Medicine (1997) Fellowship: Stanford University Pediatric Infectious Disease Fellowship (2004) Internship & Residency: Stanford Health Care at Lucile Packard Children's Hospital (1998-1999) Dr. Amieva's research investigates host-pathogen interactions at epithelial barriers, with specific expertise in Helicobacter pylori , Listeria monocytogenes , Salmonella enterica , and Staphylococcus aureus . His lab develops innovative organoid culture systems with controlled polarity to study microbial colonization and oncogenic mechanisms. Key discoveries include: H. pylori's manipulation of epithelial junctions via the CagA protein Listeria's exploitation of cell extrusion sites for invasion Staphylococcus toxin interactions with adherens junctions Gastric stem cell activation by pathogens Recent publication trends show continued leadership in infectious disease mechanisms (2020-2025), with a focus on: Pathogen-specific epithelial breach strategies Organoid modeling of viral/bacterial interactions Redox-dependent host factor regulation Single-cell spatial transcriptomic analyses Multi-institutional educational frameworks His scientific collaborations span disciplines including: Gastric cancer genomics initiatives COVID-19 lung infection models Stem cell-microbe interactions Medical education reform projects Dr. Amieva maintains active clinical research while mentoring students in both the Microbiology & Immunology and Pediatrics programs. His lab at Stanford employs advanced 3D confocal microscopy and organ-on-a-chip technologies to visualize epithelial colonization dynamics.
Rotem Karni, PhD, is an Associate Professor of Genetics at the Perelman School of Medicine, University of Pennsylvania, Philadelphia. He leads a research lab focused on understanding how alternative RNA splicing contributes to cancer and genetic diseases, with a strong emphasis on translating these findings into RNA-based therapies. Karni's lab develops decoy oligonucleotides, small molecules, and splice-switching technologies to modulate splicing factors and enhance immunotherapy. Education BSc in Biological Chemistry from The Hebrew University of Jerusalem (1997) PhD in Biological Chemistry from The Hebrew University of Jerusalem, Israel (2002) Postdoctoral Fellowship at Cold Spring Harbor Laboratory, NY (2002-2007) Karni's research explores the deregulation of alternative splicing in oncogenesis, particularly how splicing factors like RBFOX2 and S6K1 influence metastasis, DNA repair, and immune checkpoint modulation. His team investigates m6A RNA modifications for stabilizing mutant genes, with applications in Duchenne Muscular Dystrophy and pancreatic cancer. The lab's work is commercialized through biotech companies: SKIP Therapeutics, Andlit Therapeutics, and RNAble. Selected Research Trends RNA mis-splicing and neoantigen generation (2025) Splicing factor inhibition for tumor suppression (2023) Metastatic splicing signatures in pancreatic cancer (2023) Immune checkpoint splicing in cancer immunotherapy (2021) m6A modulation for mRNA stabilization (2023) Advising & Collaborations Karni has mentored numerous PhD and postdoctoral researchers, many of whom now hold leadership roles in academia, biotech, and medical institutions globally. His lab collaborates extensively on projects involving RNA innovation, including partnerships with the Institute for RNA Innovation. Contact Department of Genetics & Institute for RNA Innovation, One uCity Square, Room 4018, Philadelphia, PA 19104 Phone: 215-898-5072 Email: Rotem.Karni@Upenn.edu
Prof. Waldemar Kolanus leads the Molecular Immunology and Cell Biology department at the University of Bonn's Life & Medical Sciences Institute (LIMES) . His research bridges immunoregulation , stem cell dynamics , and metabolic stress responses in immune cells. Unit 2 member at LIMES Principal investigator in SFB 704 and ImmunoSensation Cluster Leads a multidisciplinary lab with postdocs, PhD students, and technical staff His work focuses on intracellular signaling pathways connecting immune activation to tissue homeostasis, particularly through: Cytohesin proteins in integrin-mediated adhesion and migration TRIM71 in stem cell regulation and congenital hydrocephalus High-salt environments affecting macrophage function Publication trends show expertise in immune cell migration , genetic models , and chemical inhibition , with frequent use of mice and zebrafish for in vivo studies. Key articles explore: TRIM71's dual role in auditory development and germ cell maintenance Cytohesin family's Golgi regulation and insulin signaling Ruxolitinib's off-target migration inhibition of dendritic cells Contact details: Address: LIMES Institute, Carl-Troll-Straße 31, Bonn Email: kolanus.sekretariat@uni-bonn.de Phone: +49 228 73-62788
Dr. Jose Perdomo is a Research Fellow at the Central Clinical School, Sydney Medical School, within the Faculty of Medicine and Health at the University of Sydney. He is based at the Charles Perkins Centre, where his research focuses on endothelial damage, immune complex-driven thrombosis, and platelet formation mechanisms. His work employs techniques such as flow cytometry, microfluidics, and intravital microscopy. Dr. Perdomo holds a PhD from the University of Sydney’s School of Molecular and Microbial Biosciences and received a Vice-Chancellor’s Fellowship. His research has led to two international patents and recognition, including 1st prize in the 2020 China Shenzhen Innovation Competition. His studies explore targeted inhibitors to prevent immune complex formation and thrombosis, with applications in cardiovascular health. His research interests include the interplay between white blood cells, endothelial cells, and platelets, with a focus on desialylation, apoptosis, and NETosis in immune thrombocytopenia. He has contributed to understanding vaccine-induced immune thrombocytopenia and thrombotic complications post-myocardial infarction. His findings have been featured in Nature Communications , Blood Advances , and other high-impact journals. Awards: 1st prize in China Shenzhen Innovation Competition (2020). Labs/Teams: Charles Perkins Centre, University of Sydney. Grants: Vice-Chancellor’s Fellowship (University of Sydney). Media Contributions: Insights into AstraZeneca vaccine-related blood clots featured in The Guardian , SMH , and ABC News.
Nonappa Nonappa is an Associate Professor (tenure track) in Nanochemistry at Tampere University's Faculty of Engineering and Natural Sciences since 2020. With a multidisciplinary background spanning organic chemistry, supramolecular systems, nanoparticle self-assembly, and advanced electron microscopy, he leads research at the intersection of materials science and biomedical applications. PhD in Organic Chemistry (IISc Bangalore, 2008) Docent in Soft Matter Microscopy (Aalto University, 2017) Executive MBA (Quantic School, 2020) Research focuses on bio-based optical materials using nanocellulose for sustainable photonics, breast cancer models via lab-on-a-chip systems, and precision nanomaterials through tailored self-assembly mechanisms. His team develops 3D extracellular matrices for cancer tissue culture and plasmonic nanodevices for photonic applications. Recent publications highlight gold/silver nanocluster assemblies (43+ citations in 2021-2025), electron tomography for structural analysis, and metastasis modeling systems. Key awards include Italy's Abilitazione Scientifica Nazionale (2018) and Aalto University's Docent title (2017).
Priya Raman, Ph.D., FCVS, is an Associate Professor of Integrative Medical Sciences at Northeast Ohio Medical University (NEOMED). She holds tenure and serves as Co-Director of the Basic and Translational Biomedicine (BTB) Graduate Program and Chair of the Kent State University-Biomedical Sciences Pharmacology Graduate Program. Her academic roles include teaching in NEOMED’s medical curriculum, focusing on pharmacology, cardiovascular systems, and clinical therapeutics. Raman’s research explores molecular mechanisms linking metabolic disorders (e.g., diabetes, metabolic syndrome) to vascular dysfunction and Alzheimer’s disease, using mouse models and cellular/molecular techniques. She has published extensively on thrombospondin-1, O-GlcNAc signaling, and atherosclerosis pathogenesis. Education: B.Pharm. and M.Pharm. (India), Ph.D. in Pharmacology (University of Louisiana at Monroe). She has over 25 years of postdoctoral and faculty experience, including roles at the Cleveland Clinic and Indiana University School of Medicine. Raman serves on editorial boards for journals like International Journal of Cardiology and Frontiers in Cardiovascular Medicine , and reviews grants for the American Heart Association and NIH. Research focus areas include: (1) Vascular smooth muscle cell phenotypic switching in metabolic diseases, (2) Non-lipid mechanisms of vascular disease in metabolic syndrome, and (3) Interactions between metabolic disorders and neurodegeneration. Her lab employs biochemical assays, mouse models (e.g., ApoE-/-, KKAy), and advanced imaging techniques to study these pathways. Notable recent work includes discovering that O-GlcNAc transferase deletion reduces atherosclerosis in hyperglycemic mice and identifying thrombospondin-1’s role in leptin-driven vascular pathology. She has also linked metabolic syndrome-induced O-GlcNAc deficits to Alzheimer’s-like cognitive impairment in aging mice. Raman is actively involved in interprofessional education and mentoring, directing graduate programs and teaching courses in pharmacology, molecular signaling, and diabetes/vascular disease. Her work bridges basic science and clinical applications, aiming to develop novel therapies for metabolic syndrome-related vascular complications.
Professor Hala Zreiqat AM is a leading biomedical engineer at The University of Sydney , serving as the Director of the ARC Training Centre for Innovative BioEngineering . A Fellow of all major Australian academies (AAS, ATSE, FAHMS, FRSN), she develops 3D printed bioceramics for bone regeneration while championing diversity through initiatives like the IDEAL Society and BIOTech Futures mentorship program. Her work bridges academia, clinical practice, and industry in musculoskeletal research . Research Focus: Her lab creates synthetic bone scaffolds that mimic natural bone architecture, strength, and porosity, enabling non-rejected bone regeneration via patient-matched implants. Key applications include orthopaedic, dental, and maxillofacial repair , with over $18M in competitive funding and multiple patents. Current projects explore AI-driven scaffold performance prediction and anti-senescence strategies for aging-related bone loss. Scientific Trends: Recent publications highlight 3D printed nanovoxelated ceramics , antisenescence biomaterials , and multifunctional theranostic platforms . Her team integrates machine learning for scaffold design, atom probe tomography for interface analysis, and two-photon imaging for cellular monitoring in 3D environments. 2021-2022 Fulbright Senior Scholar 2018 NSW Premier's Woman of the Year 2019 Eureka Prize for Innovative Use of Technology Fellow of Australian Academy of Science (2021) Over $18M in research funding Teaching & Leadership: She designed core courses like Tissue Engineering and Nanomaterials in Medicine , mentoring 158 students in 2020 alone. As Chair of CAAR (2020-2023), she strengthens Australia-Arab collaborations. Her lab trains early-career researchers , with alumni now in academia and industry.
Christian Friedrich Wilhelm Becker is a full Professor at the University of Vienna, holding a position within the Faculty of Chemistry and the Department of Biological Chemistry. His research profile shows extensive activity in protein chemistry and biochemistry, with particular focus on post-translational modifications and their implications in disease mechanisms. His work bridges chemical biology, biochemistry, and biomedical applications, contributing significantly to the academic and research landscape at one of Europe's oldest and most prestigious universities. Faculty of Chemistry, University of Vienna Department of Biological Chemistry Active research leader with numerous ongoing projects Significant publication record spanning multiple disciplines Professor Becker's research primarily focuses on protein chemistry, particularly post-translational modifications and their role in protein function and dysfunction. His work spans multiple interconnected areas including ubiquitination, protein aggregation, prion protein behavior, and biomimetic approaches to protein analysis. His research has significant implications for understanding neurodegenerative diseases and developing novel therapeutic approaches. The fingerprint analysis of his work shows strong connections to biochemistry, molecular biology, and chemistry, with particular emphasis on cysteine chemistry, glycosylation, and amino acid modifications. Analysis of Professor Becker's recent publications (2021-2025) reveals a consistent research trajectory focused on protein modification techniques and their biological implications. His work shows increasing sophistication in chemical biology approaches to study protein function, with particular emphasis on ubiquitination pathways and protein aggregation mechanisms. The integration of chemical synthesis methods with biological analysis represents a hallmark of his research approach. His publications span high-impact journals in biochemistry, chemical biology, and peptide science, demonstrating the interdisciplinary nature of his contributions. Professor Becker has received notable recognition for his research contributions, most prominently the Cathay Award in 2020. This award acknowledges his significant contributions to the field of protein chemistry and chemical biology. His work appears to have practical applications in therapeutic development, particularly in the areas of targeted protein degradation and immunotherapy, which likely contributed to this recognition. Cathay Award (2020) Professor Becker leads multiple significant research projects, including 'Targeted protein degradation - from small molecules to complex organelles' (2020-2024), 'Taktira: Development of an improved, low-side-effect and sustainable immunotherapy' (2019-2023), and 'Structure Zoom: Zooming in on protein functional sites with atomic resolution' (2018-2021). These projects demonstrate substantial grant funding and collaborative research efforts across multiple institutions. His active participation in 290 recorded activities through 2025 indicates a highly engaged research program with numerous collaborators and trainees. Targeted protein degradation project (2020-2024) Taktira immunotherapy project (2019-2023) Structure Zoom project (2018-2021) Professor Becker's research environment includes a robust team of collaborators and junior researchers, as evidenced by the numerous co-authored publications and activities. His work intersects with multiple research groups studying protein function, modification, and therapeutic applications. The international collaboration network shown in his profile indicates significant engagement with researchers across multiple countries, creating a dynamic research ecosystem focused on advancing protein science and its biomedical applications.
Christopher E. Nelson is an Assistant Professor in the Department of Biomedical Engineering at the University of Arkansas, College of Engineering. His lab focuses on developing biologically inspired strategies for controlled drug and gene delivery, particularly in the context of gene therapy and regenerative medicine. He is actively supported by the NIH, DoD, and Arkansas Bioscience Institute. Education: Postdoctoral Fellow – Duke University Ph.D. – Vanderbilt University B.S. – University of Arkansas Research Focus: Dr. Nelson’s lab integrates genome editing technologies with targeted delivery systems to address challenges in treating genetic diseases and promoting tissue regeneration. Major themes include CRISPR/Cas9 delivery , gene regulation in wound healing , and safe-harbor genome integration in skeletal muscle. His work spans viral and non-viral delivery vehicles , including lipid nanoparticles and AAV vectors, with a strong emphasis on preclinical validation in models of Duchenne muscular dystrophy and inflammatory disease. Scientific Awards: Controlled Release Society Postdoctoral Fellowship The Hartwell Foundation Postdoctoral Fellowship NIH Pathway to Independence Award (K99/R00) Funding & Support: The Nelson Lab is currently funded by: NIH NIGMS R35 DoD CDMRP DMD IDEA Award Arkansas Bioscience Institute University of Arkansas Engineering & Honors Colleges Lab & Team: The Nelson Lab is a dynamic, interdisciplinary team working at the intersection of gene editing, biomaterials, and regenerative medicine. They regularly present at national conferences such as ASGCT and NCUR, and mentor undergraduate researchers through SURF and Honors College grants.
Laura Solt, Ph.D. is an Associate Professor in the Department of Immunology and Microbiology at the Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology in Jupiter, Florida. She also serves as Associate Dean of the Skaggs Graduate School of Chemical and Biological Sciences. Dr. Solt began her independent research career at Scripps Florida in 2013 and has established herself as a leading researcher in nuclear receptor biology within the immune system. Her research focuses on understanding the biologically relevant roles of nuclear receptors, particularly RORα and REV-ERBs, in the immune system with emphasis on TH17 cell development and autoimmune disease. Her lab employs a multidisciplinary approach combining molecular biology, genetic techniques, and chemical biology coupled with mouse models of autoimmunity and chronic inflammation. Dr. Solt's laboratory has made significant contributions to understanding how nuclear receptors regulate immune cell function, particularly in TH17-mediated inflammation. Her work has demonstrated roles for RORα and REV-ERBs in TH17 cell development and has developed synthetic ligands to these receptors for potential therapeutic applications in autoimmune diseases. Her extensive publication record shows a clear trajectory of research focused on nuclear receptor signaling in immunity, with recent work expanding into applications for cancer immunotherapy, neuroimmunology, and metabolic aspects of immune cell function. Her articles demonstrate expertise in both basic nuclear receptor mechanisms and translational applications. Ruth L. Kirschstein National Research Service Awards (2010-2013) Dr. Solt actively mentors graduate students including Adrianna Wilson (recipient of NIDDK F31 and Scheller Graduate Student Fellowship) and Sarah Mosure (recipient of NIH NRSA F31 award and Wendy Havran award). Her laboratory receives substantial funding from multiple NIH institutes (NIDDK, NCI, NIAID, NIGMS) as well as the Crohn's & Colitis Foundation. Current research directions include investigating the roles of NR2F6 in TH17 cells, exploring RORα function in CD8 T cells, and developing novel nuclear receptor modulators for therapeutic applications.
Jonathan Conway is an Assistant Professor in the Department of Chemical and Biological Engineering at Princeton University and an associated faculty member of the High Meadows Environmental Institute (HMEI). He leads the Conway Lab, which focuses on engineering plant-microbe interactions for applications in bioagriculture, bioenergy, and biochemical industries. Education: B.S. Chemical Engineering, University of Notre Dame (2011) M.S. Chemical Engineering, North Carolina State University (2013) Ph.D. Chemical Engineering, North Carolina State University (2017) Postdoctoral Fellow, University of North Carolina Chapel Hill & Howard Hughes Medical Institute (2017-2021) Research Interests: The Conway Lab develops genetic engineering approaches for non-model bacteria at plant-microbe interfaces. Key research areas include: chemical signaling between plants and microbes, microbiome impacts on plant immunity, environmental stress responses in agricultural systems, and enzymatic degradation of lignocellulosic biomass using thermophilic bacteria. The lab employs bacterial genetics, systems biology, and biomolecular engineering to create technologies for sustainable bioindustries. Publication Trends: Recent work demonstrates strong emphasis on molecular mechanisms of plant-microbe communication (2020-2024), enzyme characterization in biomass degradation (2024-2025), and development of synthetic microbial communities for climate resilience (2024). Earlier research focused on extremophile enzymology and metabolic engineering (2012-2019). Student Advising: Currently mentors 4 graduate students and 8 undergraduates. Alumni include 9 former advisees who graduated between 2022-2024. The lab actively recruits students through Princeton's Chemical Engineering graduate program and undergraduate research initiatives. Laboratory: The Conway Lab develops microfluidic systems for root microbiome studies and genetic tools for engineering plant-associated bacteria. Current projects include designing thermophilic microbial consortia for consolidated bioprocessing and characterizing bacterial immune evasion strategies.
Prof. Veronika Somoza is a leading academic in Nutritional Systems Biology, currently affiliated with the University of Vienna and Technical University of Munich (TUM). She holds a professorship in Molecular Food Science and has led key research groups such as the Institute of Physiological Chemistry and the Christian Doppler Laboratory for Bioactive Aromatics. Her career includes roles at institutions like the German Research Institute for Food Chemistry (Garching) and the University of Wisconsin-Madison. Education: Diplom (Justus Liebig University Giessen, 1991), PhD (University of Vienna, 1995), Habilitation (Kiel University, 2002) Research Focus: Bioactive food compounds, flavor chemistry, taste receptor signaling, and gastrointestinal physiology Her work bridges food science and human health, particularly in understanding how food ingredients influence digestion, inflammation, and disease. Notable contributions include discoveries on bitter peptide effects on gastric acid secretion and flavor perception modulation. Awards: FEMA Excellence in Flavor Science (2016), ACS AGFD Fellow (2020), Hans Adolf Krebs Prize (2004) Prof. Somoza has pioneered methodologies in atomic force microscopy for foodborne virus detection and developed bitterness-masking compounds for pharmaceuticals. Her interdisciplinary approach integrates nanobiophysics with nutrition to advance functional food design and clinical applications.
Dr. Anil Kumar is an Assistant Professor in the Department of Biochemistry, Microbiology & Immunology at the University of Saskatchewan's College of Medicine. He specializes in molecular virology, focusing on positive-stranded RNA viruses and their interactions with host immune systems. His research employs high-throughput genetic screens and reverse genetics systems to identify host factors critical for viral infection. Education includes a BSc in Agricultural Sciences (1999, Kerala Agricultural University), MSc in Plant Pathology (2001, Indian Agricultural Research Institute), and PhD in Molecular Virology (2010, University of Heidelberg). Postdoctoral training included stints at the University of Heidelberg (2010–2013) and the University of Alberta (2014–2020). Research interests center on Eastern Equine Encephalitis virus (EEEV) and Enterovirus D68 (EV-D68). For EEEV, his lab investigates immune evasion mechanisms and host-virus protein interactions to identify therapeutic targets. For EV-D68, they study CNS invasion mechanisms and novel host dependency factors linked to acute flaccid myelitis (AFM). Recent work includes studies on SARS-CoV-2, uncovering roles for host proteins like Argonaute 2 in viral restriction. His lab integrates molecular biology, virology, and systems biology approaches, with a focus on translational research for antiviral drug development. Collaborations include work on respiratory syncytial virus (RSV) entry mechanisms and dengue virus replication regulation.
Professor Marek Sanak serves as Full Professor at the Department of Internal Medicine, Jagiellonian University Medical College in Cracow, Poland. He concurrently holds leadership positions as Acting Director of the Department of Forensic Medicine, Head of the Division of Molecular Biology and Clinical Genetics, and Vice-Rector for Research and International Cooperation since 2016. His academic foundation includes: MD from Jagiellonian University Medical College Specialization in Pediatrics and Genetics PhD from Jagiellonian University Research appointments at Harvard University, University of Paris VI, and University of Zurich Professor Sanak's research integrates clinical genetics with molecular immunology, focusing on asthma pathogenesis, lipid mediators of inflammation, and genetic diagnostics. His laboratory employs advanced techniques including deep DNA/RNA sequencing to identify biomarkers and elucidate disease mechanisms. The work bridges fundamental molecular discoveries with clinical applications in respiratory diseases, allergic disorders, and forensic medicine, demonstrating particular expertise in aspirin-exacerbated respiratory disease and epigenetic regulation of inflammatory pathways. Analysis of his recent publications reveals a strategic evolution from classical asthma research toward molecular genetics and viral pathogenesis. His 2017-2021 work increasingly incorporates epigenetic approaches (DNA methylation, microRNA profiling) while expanding into SARS-CoV-2 research during the pandemic. The publications demonstrate interdisciplinary integration across immunology, respiratory medicine, and molecular diagnostics, with consistent focus on translational applications. His distinguished career has been recognized through numerous honors: The Lancet Investigators Award on Asthma (1997) Polish Ministry of Health Individual Prize (1999) Jagiellonian Laurel (2012) Pro Arte Docendi Award (2014/15) Gold Medal for Long Service (2019) Top 2% of world scientists ranking (Elsevier 2022) As Vice-Rector for Research, Professor Sanak has significantly expanded international collaborations with King's College London, University of Southampton, and University of Zurich. His leadership has secured substantial funding for molecular diagnostics and inflammatory disease research while mentoring numerous early-career researchers. He delivers invited lectures globally for organizations including the American Thoracic Society and European Academy of Allergy and Clinical Immunology. Professor Sanak directs integrated research units across the Division of Molecular Biology and Clinical Genetics, Division of Biochemical and Molecular Diagnostics at University Hospital Cracow, and the Department of Forensic Medicine. These teams combine clinical service with basic research to advance genetic diagnostics and understand disease mechanisms, maintaining forensic genetics expertise developed over 20 years of practice.
